ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Articles

Mitsubishi Tanabe Pharma to step up US drug sales

OSAKA -- Mitsubishi Tanabe Pharma will spend more than 200 billion yen ($1.61 billion) over the five years ending fiscal 2020 to expand new-drug sales in the American market under a medium-term business plan announced Monday.

     "We will develop sales channels utilizing such approaches as mergers and acquisitions, and we project sales of approximately 80 billion yen in the U.S. in fiscal 2020," President Masayuki Mitsuka told a news conference here. Medicines bound for that market include a treatment for Lou Gehrig's disease, or amyotrophic lateral sclerosis, and a flu vaccine under development.

     The drug company targets global group sales of 500 billion yen, up from the 411 billion yen estimated for fiscal 2015. Mitsubishi Tanabe also aims to boost net profit from the 47 billion yen estimate to 70 billion yen. And it wants to grow the ratio of overseas sales from 25% to 40%.

     Mitsubishi Tanabe Pharma is acting ahead of the 2019 expiration of patent protection on Gilenya, a multiple sclerosis treatment licensed to Swiss drugmaker Novartis.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more